TY  - JOUR
A1  - Mansour, Ahmad M.
A1  - Arevalo, J. Fernando
A1  - Al Kahtani, Eman
A1  - Zegarra, Hernando
A1  - Abboud, Emad
A1  - Anand, Rajiv
A1  - Ahmadieh, Hamid
A1  - Sisk, Robert A.
A1  - Mirza, Salman
A1  - Tuncer, Samuray
A1  - Navea Tejerina, Amparo
A1  - Mataix, Jorge
A1  - Ascaso, Francisco J.
A1  - Pulido, Jose S.
A1  - Guthoff, Rainer
A1  - Goebel, Winfried
A1  - Roh, Young Jung
A1  - Banker, Alay S.
A1  - Gentile, Ronald C.
A1  - Alonso Martinez, Isabel
A1  - Morris, Rodney
A1  - Panday, Neeraj
A1  - Min, Park Jung
A1  - Merce, Emilie
A1  - Lai, Timothy Y. Y.
A1  - Massoud, Vicky
A1  - Ghazi, Nicola G.
T1  - Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
JF  - Journal of Ophtamology
N2  - We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0.001), 105.3 microns at 1 year (n = 10; P = 0.03), and 157.6 microns at 2 years (n = 7; P = 0.08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P < 0.001), 2.8 lines (n = 20; P = 0.01) at 1 year, and 3.1 lines (n = 13; P = 0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.
KW  - membrane
KW  - photodynamic therapy
KW  - secondary
KW  - bevacizumab
KW  - ranibizumab
KW  - patient
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117923
IS  - 210458
ER  -